Kymera Therapeutics Receives IND Clearance for KT-333, a

kilat 333KT-333 is the first heterobifunctional degrader against an undrugged transcription factor to enter clinical development. In November 2021, Kymera announced that multiple abstracts wereKILAT333 : Situs Modal Deposit Irit Hasil Selangit. User Avatar. DAFTAR & LOGIN SITUS KILAT333. share icon. Send Message. close button.